Cingulate Inc. (NASDAQ:CING – Get Free Report) was up 5.6% during trading on Friday . The stock traded as high as $0.69 and last traded at $0.69. Approximately 506,862 shares traded hands during trading, a decline of 1% from the average daily volume of 511,132 shares. The stock had previously closed at $0.65.
Cingulate Stock Performance
The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.19 and a current ratio of 0.19. The stock has a market cap of $10.80 million, a P/E ratio of -0.41 and a beta of -0.49. The firm’s 50 day moving average is $0.66 and its 200 day moving average is $0.91.
Insider Buying and Selling
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new position in Cingulate during the 1st quarter valued at approximately $103,000. Renaissance Technologies LLC acquired a new position in Cingulate during the 1st quarter valued at approximately $100,000. Prime Capital Investment Advisors LLC acquired a new position in Cingulate during the 1st quarter valued at approximately $48,000. State Street Corp acquired a new stake in shares of Cingulate in the first quarter worth $44,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Cingulate in the fourth quarter worth $34,000. Institutional investors and hedge funds own 3.75% of the company’s stock.
Cingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults.
- Five stocks we like better than Cingulate
- What is the price-to-earnings growth (PEG) ratio?
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- How to Capture the Benefits of Dividend Increases
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
- Why Consider Investing in Nanotechnology Stocks
- Name A Better Trio Than These Underrated High Potential Stocks
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.